Table 5. Patient characteristics at study entry by treatment arm, limited to women with BMI≥25 kg/m2.
| Initial ART includes: | |||
| Variable | Stavudine | Zidovudine | p-value1 |
| Number (patient years follow-up) | 194 (274) | 132 (190) | |
| Age (years) Mean (SD) | 36 (7) | 38 (9) | .03 |
| Patient years of follow up Mean (SD) | 1.4 (0.6) | 1.4 (0.6) | .64 |
| BMI (kg/m2) Median (IQR) | 27 (26, 30) | 30 (29, 34) | <.0001 |
| CD4 (cells/mm3) Median (IQR) | 99 (64) | 122 (58) | .0003 |
| Creatinine (mg/dL) Median (IQR) | 0.85 (0.77, 0.94) | 0.88 (0.80, 0.98) | .02 |
| ALT (IU/L) Median (IQR) | 22 (17, 32) | 22 (17, 30) | .97 |
| Albumin (g/L) Median (IQR) | 32 (6) | 36 (4) | <.0001 |
| Hemoglobin (g/dL) Median (IQR) | 11.1 (1.7) | 11.7 (1.1) | .0001 |
1
T-test for continuous where mean and standard deviation reported, and Wilcoxon rank sum where median and IQR reported.